Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual MeetingBusiness Wire • 05/26/22
CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)PRNewsWire • 05/20/22
FDA approves Eli Lilly and Incyte's Olumiant for treatment of certain hospitalized adults with COVID-19Market Watch • 05/11/22
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19PRNewsWire • 05/11/22
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host DiseaseBusiness Wire • 05/05/22
Incyte's (INCY) CEO Hervé Hoppenot on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/03/22
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsBusiness Wire • 05/03/22
Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in JapanBusiness Wire • 04/28/22
Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung CancerBusiness Wire • 04/22/22
Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 StudiesPRNewsWire • 03/26/22
Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With VitiligoBusiness Wire • 03/26/22
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host DiseaseBusiness Wire • 03/25/22